Kinesin inhibitor marches toward first-in-class pivotal trial

Raltegravir: first in class HIV integrase inhibitor

On October 16, 2007, the US Food and Drug Administration (FDA) approved raltegravir for treatment of human immunodeficiency virus (HIV)-1 infection in combination with other antiretroviral agents in treatment-experienced adult patients who have evidence of viral replication and HIV-1 strains resistant to multiple antiretroviral agents. Raltegravir is first in a novel class of antiretroviral dru...

Kinesin-5 inhibitor resistance is driven by kinesin-12

The microtubule (MT) cytoskeleton bipolarizes at the onset of mitosis to form the spindle. In animal cells, the kinesin-5 Eg5 primarily drives this reorganization by actively sliding MTs apart. Its primacy during spindle assembly renders Eg5 essential for mitotic progression, demonstrated by the lethal effects of kinesin-5/Eg5 inhibitors (K5Is) administered in cell culture. However, cultured ce...

FIRST SURVEY OF FACTOR IX INHIBITOR IN NORTHEASTERN IRAN

Antitumor activity of a kinesin inhibitor.

Several members of the kinesin family of microtubule motor proteins play essential roles in mitotic spindle function and are potential targets for the discovery of novel antimitotic cancer therapies. KSP, also known as HsEg5, is a kinesin that plays an essential role in formation of a bipolar mitotic spindle and is required for cell cycle progression through mitosis. We identified a potent inhi...

Phleogena faginea, first report from class Atractiellomycetes in Iran

In the framework of collecting and identifying of fungi of Iran, specimens of an interesting fungus were collected and identified as Phleogena faginea (Fr.) Link based on Oberwinkler & Bandoni (1982). The characteristic features of specimens were as follows.